Revolution Medicines, Inc. - Revizia istoricului

127.0.0.1: The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).

2024-11-28T03:41:55Z

The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).

← Versiunea anterioară		Versiunea de la data 28 noiembrie 2024 06:41
Linia 2:		Linia 2:

	==Descriere companie==		==Descriere companie==
	Revolution Medicines, Inc. (https://www.revmed.com/) is a clinical-stage precision oncology company. The Company is focused on developing targeted therapies to inhibit elusive frontier targets within notorious growth and survival pathways, with particular emphasis on the renin angiotensin system (RAS) and mammalian target of rapamycin (mTOR) signaling pathways. The Company’s pipeline includes RMC-4630, a clinical-stage drug candidate that is designed to selectively inhibit the activity of SHP2. Additionally, the Company is developing a portfolio of inhibitors of other key frontier oncology targets within the notorious RAS pathway, as well as the related mTOR signaling cascade. These include inhibitors of multiple mutant RAS proteins and son of sevenless homolog [[one]] (SOS1), as well as RMC-5552. RMC-5552 is a selective inhibitor of mammalian target of rapamycin complex one (mTORC1) that is designed to preserve the tumor suppressive activity.		Revolution Medicines, Inc. (https://www.revmed.com/) is a clinical-stage precision oncology company. The Company is focused on developing targeted therapies to inhibit elusive frontier targets within notorious growth and survival pathways, with particular emphasis on the renin angiotensin system (RAS) and mammalian target of rapamycin (mTOR) signaling pathways. The Company’s pipeline includes RMC-4630, a clinical-stage drug candidate that is designed to selectively inhibit the activity of SHP2. Additionally, the Company is developing a portfolio of inhibitors of other key frontier oncology targets within the notorious RAS pathway, as well as the related mTOR signaling cascade. These include inhibitors of multiple mutant RAS proteins and son of sevenless homolog [[one]] (SOS1), as well as RMC-5552. RMC-5552 is a selective inhibitor of mammalian target of rapamycin complex [[ONE\|one]] (mTORC1) that is designed to preserve the tumor suppressive activity.

	==Grafic actiuni companie==		==Grafic actiuni companie==

127.0.0.1: The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).

2024-10-03T04:17:32Z

The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).

← Versiunea anterioară		Versiunea de la data 3 octombrie 2024 07:17
Linia 2:		Linia 2:

	==Descriere companie==		==Descriere companie==
	Revolution Medicines, Inc. (https://www.revmed.com/) is a clinical-stage precision oncology company. The Company is focused on developing targeted therapies to inhibit elusive frontier targets within notorious growth and survival pathways, with particular emphasis on the renin angiotensin system (RAS) and mammalian target of rapamycin (mTOR) signaling pathways. The Company’s pipeline includes RMC-4630, a clinical-stage drug candidate that is designed to selectively inhibit the activity of SHP2. Additionally, the Company is developing a portfolio of inhibitors of other key frontier oncology targets within the notorious RAS pathway, as well as the related mTOR signaling cascade. These include inhibitors of multiple mutant RAS proteins and son of sevenless homolog one (SOS1), as well as RMC-5552. RMC-5552 is a selective inhibitor of mammalian target of rapamycin complex one (mTORC1) that is designed to preserve the tumor suppressive activity.		Revolution Medicines, Inc. (https://www.revmed.com/) is a clinical-stage precision oncology company. The Company is focused on developing targeted therapies to inhibit elusive frontier targets within notorious growth and survival pathways, with particular emphasis on the renin angiotensin system (RAS) and mammalian target of rapamycin (mTOR) signaling pathways. The Company’s pipeline includes RMC-4630, a clinical-stage drug candidate that is designed to selectively inhibit the activity of SHP2. Additionally, the Company is developing a portfolio of inhibitors of other key frontier oncology targets within the notorious RAS pathway, as well as the related mTOR signaling cascade. These include inhibitors of multiple mutant RAS proteins and son of sevenless homolog [[one]] (SOS1), as well as RMC-5552. RMC-5552 is a selective inhibitor of mammalian target of rapamycin complex one (mTORC1) that is designed to preserve the tumor suppressive activity.

	==Grafic actiuni companie==		==Grafic actiuni companie==

Admin: Pagină nouă: Pagina dedicata companiei Revolution Medicines, Inc. listata cu simbolul US.RVMD ==Descriere companie== Revolution Medicines, Inc. (https://www.revmed.com/) is a clinical-stage precision oncology company. The Company is focused on developing targeted therapies to inhibit elusive frontier targets within notorious growth and survival pathways, with particular emphasis on the renin angiotensin system (RAS) and mammalian target of rapamycin (mTOR) signaling pathways. The Company...

2024-09-18T18:26:38Z

Pagină nouă: Pagina dedicata companiei Revolution Medicines, Inc. listata cu simbolul US.RVMD ==Descriere companie== Revolution Medicines, Inc. (https://www.revmed.com/) is a clinical-stage precision oncology company. The Company is focused on developing targeted therapies to inhibit elusive frontier targets within notorious growth and survival pathways, with particular emphasis on the renin angiotensin system (RAS) and mammalian target of rapamycin (mTOR) signaling pathways. The Company...

Pagină nouă

Pagina dedicata companiei Revolution Medicines, Inc. listata cu simbolul US.RVMD

==Descriere companie==
Revolution Medicines, Inc. (https://www.revmed.com/) is a clinical-stage precision oncology company. The Company is focused on developing targeted therapies to inhibit elusive frontier targets within notorious growth and survival pathways, with particular emphasis on the renin angiotensin system (RAS) and mammalian target of rapamycin (mTOR) signaling pathways. The Company’s pipeline includes RMC-4630, a clinical-stage drug candidate that is designed to selectively inhibit the activity of SHP2. Additionally, the Company is developing a portfolio of inhibitors of other key frontier oncology targets within the notorious RAS pathway, as well as the related mTOR signaling cascade. These include inhibitors of multiple mutant RAS proteins and son of sevenless homolog one (SOS1), as well as RMC-5552. RMC-5552 is a selective inhibitor of mammalian target of rapamycin complex one (mTORC1) that is designed to preserve the tumor suppressive activity.

==Grafic actiuni companie==
<iframe key="tradeville" path="graficSimbol/US.RVMD" />

==Ultimele stiri despre Revolution Medicines, Inc. (US.RVMD)==
<dynamicpagelist>
category=US.RVMD
count=10
order=descending
addfirstcategorydate=false
</dynamicpagelist>

[[Categorie:US.RVMD]][[Categorie:Stiri despre companii]]